A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer’s disease

Psychopharmacology

Volumn 233, Issue 18, 2016, Pages 3371-3381

  Reeves, Suzanne ^a,b   Bertrand, Julie ^a   D’Antonio, Fabrizia ^a,b   McLachlan, Emma ^b   Nair, Akshay ^a   Brownings, Stuart ^b   Greaves, Suki ^c   Smith, Alan ^c   Taylor, David ^c   Howard, Robert ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Age; Alzheimer s disease; Amisulpride; Antipsychotic; Elderly; Population pharmacokinetics

Indexed keywords

AMISULPRIDE; CREATININE; NEUROLEPTIC AGENT; SULPIRIDE; SULTOPRIDE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; SULPIRIDE;

EID: 84982836721     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-016-4379-6     Document Type: Article

References (46)

1. Akil A et al. (2016) A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer’s disease patients with agitation. J Pharmacokinet Pharmacodyn 43:99–109. doi:10.1007/s10928-015-9457-6
2. Bergemann N, Kopitz J, Kress KR, Frick A (2004) Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 14:245–250. doi:10.1016/j.euroneuro.2003.09.001
3. Bigos KL, Chew ML, Bies RR (2008a) Pharmacokinetics in geriatric psychiatry. Curr Psychiatry Rep 10:30–36
4. Bigos KL et al. (2008b) Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 48:157–165
5. Bowskill SV, Patel MX, Handley SA, Flanagan RJ (2012) Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002-2010. Humanist Psychol 27:507–513. doi:10.1002/hup.2256
6. Clark-Papasavas C et al. (2014) Towards a therapeutic window of D2/3 occupancy for treatment of psychosis in Alzheimer’s disease, with [18F]fallypride positron emission tomography. Int J Geriatr Psychiatry 29:1001–1009. doi:10.1002/gps.4090
7. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
8. Coukell ALSC, Benfield P (1996) Amisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 6:237–256
9. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308–2314
10. Dos Santos Pereira JN et al. (2014) The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family. AAPS J 16:1247–1258. doi:10.1208/s12248-014-9649-9
11. Duffull SB, Wright DF, Winter HR (2011) Interpreting population pharmacokinetic-pharmacodynamic analyses—a clinical viewpoint. Br J Clin Pharmacol 71:807–814. doi:10.1111/j.1365-2125.2010.03891.x
12. Dufour A, Desanti C (1988) Pharmacokinetics and metabolism of amisulpride. Ann Psychiatr 3:298–305
13. Ette EI, Williams PJ, Lane JR (2004) Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic studies. Ann Pharmacother 38:2136–2144. doi:10.1345/aph.1E260
14. Feng Y et al. (2008) Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol 66:629–639. doi:10.1111/j.1365-2125.2008.03276.x
15. Folstein MF, Folstein SE, McHugh PR (1975) “mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198
16. Graff-Guerrero A et al. (2015) Evaluation of antipsychotic dose reduction in late-life schizophrenia: a prospective dopamine D2/3 receptor occupancy study. JAMA Psychiatry 72:927–934. doi:10.1001/jamapsychiatry.2015.0891
17. Haenisch B, Drescher E, Thiemer L, Xin H, Giros B, Gautron S, Bonisch H (2012) Interaction of antidepressant and antipsychotic drugs with the human organic cation transporters hOCT1, hOCT2 and hOCT3. Naunyn Schmiedeberg's Arch Pharmacol 385:1017–1023. doi:10.1007/s00210-012-0781-8
18. Hamon-Vilcot B et al. (1998) Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. Eur J Clin Pharmacol 54:405–409
19. Hiemke C et al. (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44:195–235. doi:10.1055/s-0031-1286287
20. Holford NH (1996) A size standard for pharmacokinetics. Clin Pharmacokinet 30:329–332
21. Jennum P, Baandrup L, Ibsen R, Kjellberg J (2015) Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: a population-based register study. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 25:1906–1913. doi:10.1016/j.euroneuro.2015.08.014
22. Jeste DV et al. (2008) ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 33:957–970
23. Jonker JW, Schinkel AH (2004) Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 308:2–9. doi:10.1124/jpet.103.053298
24. Kuhn E, Lavielle M (2005) Maximum likelihood estimation in non-linear mixed effects models. Comput Stat Data Anal 49:1020–1038
25. Lako IM, van den Heuvel ER, Knegtering H, Bruggeman R, Taxis K (2013) Estimating dopamine D(2) receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol 33:675–681. doi:10.1097/JCP.0b013e3182983ffa
26. Leon C, Gerretsen P, Uchida H, Suzuki T, Rajji T, Mamo DC (2010) Sensitivity to antipsychotic drugs in older adults. Curr Psychiatry Rep 12:28–33. doi:10.1007/s11920-009-0080-3
27. Lim HK, Pae CU, Lee C, Lee CU (2006) Amisulpride versus risperidone treatment for behavioral and psychological symptoms in patients with dementia of the Alzheimer type: a randomised, open, prospective study. Neuropsychobiology 54:247–251
28. Lotrich FE, Bies RR, Smith GS, Pollock BG (2006) Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. J Psychopharmacol 20:33–40. doi:10.1177/1359786806066044
29. Mangoni AA, Jackson SH (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6–14
30. Mauri M, Mancioli A, Rebecchi V, Corbetta S, Colombo C, Bono G (2006) Amisulpride in the treatment of behavioural disturbances among patients with moderate to severe Alzheimer’s disease. Acta Neurol Scand 114:97–101. doi:10.1111/j.1600-0404.2006.00660.x
31. Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, Di Pace C, Altamura AC (2014) Clinical pharmacology of atypical antipsychotics: an update. EXCLI J 13:1163–1191
32. Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, Kales HC (2015) Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry 72:438–445. doi:10.1001/jamapsychiatry.2014.3018
33. McKeith IG et al. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124
34. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–944
35. Merle L, Laroche ML, Dantoine T, Charmes JP (2005) Predicting and preventing adverse drug reactions in the very old. Drugs Aging 22:375–392
36. Mould DR et al. (2002) Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 71:334–348. doi:10.1067/mcp.2002.123553
37. Muller MJ, Eich FX, Regenbogen B, Sachse J, Hartter S, Hiemke C (2009) Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. J Psychopharmacol 23:278–286. doi:10.1177/0269881108089806
38. Muller MJ, Regenbogen B, Hartter S, Eich FX, Hiemke C (2007) Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res 41:673–679. doi:10.1016/j.jpsychires.2005.10.003
39. Muller MJ, Regenbogen B, Sachse J, Eich FX, Hartter S, Hiemke C (2006) Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. Pharmacopsychiatry 39:41–46. doi:10.1055/s-2006-931540
40. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G (2002) A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Humanist Psychol 17:1–13. doi:10.1002/hup.320
41. Samson A, Lavielle M (2006) Extension of the SAEM algorithm to left-censored data in nonlinear nixed-effects model: application to HIV dynamics model. Comput Stat Data Anal 51:1562–1574
42. Seeman P (2014) Therapeutic occupation of dopamine D2 antipsychotic receptors in Alzheimer’s disease. Int J Geriatr Psychiatry 29:1096 doi:10.1002/gps.4133
43. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11–19
44. Sparshatt A, Taylor D, Patel MX, Kapur S (2009) Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta Psychiatr Scand 120:416–428. doi:10.1111/j.1600-0447.2009.01429.x
45. Uchida H, Kapur S, Mulsant BH, Graff-Guerrero A, Pollock BG, Mamo DC (2009a) Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry 17:255–263
46. Uchida H, Mamo DC, Mulsant BH, Pollock BG, Kapur S (2009b) Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry 70:397–405